Strykagen

Becker muscular dystrophy (BMD) results from dystrophin-gene mutations that produce truncated, partially functional dystrophin and progressive muscle disease. It occurs in 3–6 per 100,000 male births; symptoms appear at ages 8–15.

Duchenne muscular dystrophy (DMD) affects 1 in 3,500 male births. Mutations in the X-chromosome dystrophin gene cause the absence of functional dystrophin, compromising the linkage between muscle fibers and the sarcolemma.

Integrin therapeutics for the treatment of muscular dystrophy

David A. Maine oversees business operations for Strykagen’s muscular dystrophy therapeutics and is involved in their commercialization. David A. Maine has more than 15 years of managerial experience.

Dr. Dean J. Burkin was the first to show that alpha7beta1 integrin can serve as a surrogate for dystrophin loss in DMD. Dr. Burkin led studies on laminin-111 protein as a substitute for merosin loss in Laminin-α2 congenital muscular dystrophy.

Dr. Ryan D. Wuebbles oversees Strykagen's R&D and co-invented patented technologies licensed by the company. His research spans biochemistry, drug development, molecular biology, genetic analysis, DNA engineering, and animal model development.

For Scientific Information please contact:

Strykagen Corp is located at the University Nevada School of Medicine. This laboratory space is fully equipped for modern molecular and cell biology for the development of therapies, diagnostics and biomarkers for the muscular dystrophies.

Strykagen Corp is located at the University Nevada School of Medicine. This laboratory space is fully equipped for modern molecular and cell biology for the development of therapies, diagnostics and biomarkers for the muscular dystrophies.